Of course I’ll live blog it — will there be an actual, rather than rumored settlement of the Centocor/J&J $10 billion arbitration to report, by then?
Will currencies have dampened full-year sales by more than 4 percent?
Will CEO Frazier be ready to announce an intention to wholly-exit the Consumer Health businesses [as his counterpart at the (no relation) German Merck just did]?
We shall see. The some 20 analysts covering Merck (per Yahoo! Biz), on average, expect non-GAAP 2010 EPS of $3.38, on sales of $45.48 billion.
The company itself last said (on pain of SEC liability) that it “expected full year 2010 non-GAAP EPS to be between $3.27 and $3.41, excluding certain items and a 2010 GAAP EPS range of $1.15 to $1.50.” Do stop back:
. . . .Q4 2010 Merck & Co., Inc. Earnings Conference Call
Thursday, February 3, 2011 8:00 a.m. ET
Click here to listen with Windows Media. . . .